Top-News

Leap Therapeutics Aktie News

Aktie
WKN:  A3EMJP ISIN:  US52187K2006 US-Symbol:  LPTX Branche:  Biotechnologie Land:  USA
1,15 $
-0,12 $
-9,45%
0,9877 € 20:00:50 Uhr
Depot/Watchlist
Marktkapitalisierung *
98,06 Mio. €
Streubesitz
59,37%
KGV
-1,75
Index-Zuordnung
-

Leap Therapeutics News

06.01.25 - PR Newswire
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire
26.11.24 - PR Newswire
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference PR Newswire
13.11.24 - PR Newswire
Leap Therapeutics Reports Third Quarter 2024 Financial Results
Leap Therapeutics Reports Third Quarter 2024 Financial Results PR Newswire
30.09.24 - PR Newswire
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients PR Newswire
12.08.24 - PR Newswire
Leap Therapeutics Reports Second Quarter 2024 Financial Results
Leap Therapeutics Reports Second Quarter 2024 Financial Results PR Newswire
13.05.24 - PR Newswire
Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire
18.03.24 - PR Newswire
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire
16.01.24 - PR Newswire
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium PR Newswire
02.01.24 - PR Newswire
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients PR ...
11.12.23 - PR Newswire
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO ...
21.11.23 - PR Newswire
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference PR Newswire
13.11.23 - PR Newswire
Leap Therapeutics Reports Third Quarter 2023 Financial Results
Leap Therapeutics Reports Third Quarter 2023 Financial Results PR Newswire
05.09.23 - PR Newswire
Leap Therapeutics to Participate at Upcoming Investor Conferences
Leap Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
14.08.23 - PR Newswire
Leap Therapeutics Reports Second Quarter 2023 Financial Results
Leap Therapeutics Reports Second Quarter 2023 Financial Results PR Newswire
12.07.23 - PR Newswire
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients PR Newswire
20.06.23 - PR Newswire
Leap Therapeutics Announces Reverse Stock Split
Leap Therapeutics Announces Reverse Stock Split PR Newswire
25.05.23 - PR Newswire
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO ...
18.05.23 - PR Newswire
Thinking about buying stock in X4 Pharmaceuticals, Snowflake, Leap Therapeutics, Arbor Realty, or Microvision?
Thinking about buying stock in X4 Pharmaceuticals, Snowflake, Leap Therapeutics, Arbor Realty, or Microvision? PR Newswire
15.05.23 - PR Newswire
Leap Therapeutics Reports First Quarter 2023 Financial Results
Leap Therapeutics Reports First Quarter 2023 Financial Results PR Newswire
26.04.23 - PR Newswire
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO ...

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »